Branched stented anastomosis frozen elephant trunk repair: Early results from a physician-sponsored investigational device exemption study
Eric E Roselli,Patrick R Vargo,Faisal Bakaeen,Marijan Koprivanac,Daniel Burns,Yuki Kuramochi,Marc Gillinov,B-SAFER Investigators,Edward Soltesz,Michael Tong,Shinya Unai,Haytham Elgharably,Xiaoying Lou,Francis Caputo,Levester Kirksey,Jonathong Quatromoni,Ali Khalifeh,Viral Patel,Frank Cikach,James Witten,Andrew Tang,Bradley Roskinski,Emily Vianna,Michael Javorski,Karolis Bauza,Benjamin Kramer,Juan Bernardo Umana,Shawn Shah,Nicholas Oh,Benjamin Yang,Haley Jenkins,William Frankel,Davut Cekmecelioglu,Rohun Bhagat,Nadia Bakir,Adam Daly,Raed Abdulkareem,Andrea Steely,Jorge Balzan,Anibel Ibanez,SriKrishna Modugula
DOI: https://doi.org/10.1016/j.jtcvs.2023.09.069
Abstract:Background: Multisegment thoracic aortic disease typically requires total aortic arch replacement, affects a heterogenous population, and carries a high risk even at centers of excellence. Risk has been associated with the duration of operation and complexity of repair. A novel branched stented anastomosis frozen elephant trunk repair (B-SAFER) technique has been developed at our center and is currently being studied as a physician-sponsored investigation device exemption (PS-IDE). Objective: This study aimed to assess the early safety of using this investigational technique to treat the proximal aorta in subjects with aortic disease involving multiple segments. Methods: This prospective, single center, nonrandomized study enrolled patients undergoing B-SAFER for acute aortic syndrome (n = 73), aortic aneurysm with chronic aortic dissection (n = 68), degenerative aortic aneurysm (n = 33), or congenital aortic arch disease (n = 4). Devices are delivered antegrade under hypothermic circulatory arrest, and the arch reconstruction is performed as a single anastomosis single stent (SASS; n = 70), single anastomosis multiple stent (SAMA; n = 68), multiple anastomosis single stent (MASS; n = 21), or multiple anastomosis multiple stent (MAMS; n = 16) reconstruction. The primary safety endpoints were operative mortality, disabling stroke, and paraparesis/paralysis. Results: Between May 27, 2021, and December 31, 2022, 178 patients underwent B-SAFER in the configurations and for the indications as described above. The median patient age was 65 years (range, 21 to 85 years), and 52 (29%) were female. The median cardiopulmonary bypass time was 188 minutes (interquartile range [IQR], 155 to 226 minutes), and 97% of the patients underwent repair with antegrade brain perfusion for a median of 46 minutes (IQR, 38 to 61 minutes). Operative mortality occurred in 10 patients (5.6%, including 6 [8.2%] with acute dissection, 2 [2.9%] with chronic dissection, 2 [6.1%] with degenerative aneurysm, and 0 with a congenital disorder), disabling stroke in 5 patients (2.9%), and paraparesis in 1 patient. Other serious complications included respiratory failure (n = 20; 11.4%) and acute kidney injury (n = 18; 10%). Thirty-two patients (18%) had undergone second-stage repairs (28 endovascular and 4 open), with 1 operative mortality after that procedure due to distal rupture. Estimated survival was 95% at 30 days, 88% at 90 days, 84% at 6 months, and 79% at 1 year. One-year survival differed by indication (72% for acute dissection, 91% for chronic dissection, 71% for degenerative aneurysm, and 100% for congenital disorders). Conclusions: The B-SAFER technique for total arch replacement in a complex cohort of patients with various indications for surgery is a safe and reproducible operation, as demonstrated by the early results from a very inclusive PS-IDE study. Further follow-up and analysis will help refine the technique. Novel devices to perform this procedure should be developed.